BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 20640598)

  • 1. Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5.
    de Lurdes Agostinho Cabrita A; Pinho A; Malho A; Morgado E; FaĆ­sca M; Carrasqueira H; Silva AP; Neves PL
    Int Urol Nephrol; 2011 Sep; 43(3):835-40. PubMed ID: 20640598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.
    Ogawa T; Shimizu H; Kyono A; Sato M; Yamashita T; Otsuka K; Nitta K
    Int Urol Nephrol; 2014 Jan; 46(1):151-9. PubMed ID: 23807369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial).
    Kato H; Nangaku M; Hirakata H; Wada T; Hayashi T; Sato H; Yamazaki Y; Masaki T; Kagimura T; Yamamoto H; Hase H; Kamouchi M; Imai E; Mizuno K; Iwasaki M; Akizawa T; Tsubakihara Y; Maruyama S; Narita I
    Clin Exp Nephrol; 2018 Feb; 22(1):78-84. PubMed ID: 28660446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study.
    Galle JC; Claes K; Kiss I; Winearls CG; Herlitz H; Guerin A; Di Giulio S; Suranyi MG; Bridges I; Addison J; Farouk M
    Nephrol Dial Transplant; 2012 Jun; 27(6):2303-11. PubMed ID: 22140136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
    Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Hamilton L; Bridges K; Pujol B
    BMC Cancer; 2009 Sep; 9():311. PubMed ID: 19728887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Responsiveness to erythropoiesis-stimulating agents and renal survival in patients with chronic kidney disease.
    Kuwahara M; Mandai S; Kasagi Y; Kusaka K; Tanaka T; Shikuma S; Akita W
    Clin Exp Nephrol; 2015 Aug; 19(4):598-605. PubMed ID: 25183365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial).
    Imai E; Maruyama S; Nangaku M; Hirakata H; Hayashi T; Narita I; Kono H; Nakatani E; Morita S; Tsubakihara Y; Akizawa T
    Clin Exp Nephrol; 2016 Feb; 20(1):71-6. PubMed ID: 26081567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
    Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.
    Koulouridis I; Alfayez M; Trikalinos TA; Balk EM; Jaber BL
    Am J Kidney Dis; 2013 Jan; 61(1):44-56. PubMed ID: 22921639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early response to erythropoiesis-stimulating agents in non-dialysis chronic kidney disease patients.
    Kuwahara M; Arai Y; Takehara E; Sasaki Y; Yoshimine T; Kusaka K; Shikuma S; Akita W; Uchida S
    Clin Exp Nephrol; 2016 Aug; 20(4):585-594. PubMed ID: 26511877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
    Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UK Renal Registry 16th annual report: chapter 10 haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2012: national and centre-specific analyses.
    Rao A; Gilg J; Williams A
    Nephron Clin Pract; 2013; 125(1-4):183-208. PubMed ID: 24662174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis.
    Abu-Alfa AK; Sloan L; Charytan C; Sekkarie M; Scarlata D; Globe D; Audhya P
    Curr Med Res Opin; 2008 Apr; 24(4):1091-100. PubMed ID: 18328118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.
    Macdougall IC; Walker R; Provenzano R; de Alvaro F; Locay HR; Nader PC; Locatelli F; Dougherty FC; Beyer U;
    Clin J Am Soc Nephrol; 2008 Mar; 3(2):337-47. PubMed ID: 18287255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
    Yong K; Kairaitis L
    Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
    Solomon SD; Uno H; Lewis EF; Eckardt KU; Lin J; Burdmann EA; de Zeeuw D; Ivanovich P; Levey AS; Parfrey P; Remuzzi G; Singh AK; Toto R; Huang F; Rossert J; McMurray JJ; Pfeffer MA;
    N Engl J Med; 2010 Sep; 363(12):1146-55. PubMed ID: 20843249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of gender and dialysis adequacy on anaemia in peritoneal dialysis.
    Ryta A; Chmielewski M; Debska-Slizien A; Jagodzinski P; Sikorska-Wisniewska M; Lichodziejewska-Niemierko M
    Int Urol Nephrol; 2017 May; 49(5):903-908. PubMed ID: 28058668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of anemia correction by erythropoiesis-stimulating agents on cardiovascular function in non-dialysis patients with chronic kidney disease.
    Suzuki M; Hada Y; Akaishi M; Hiroe M; Aonuma K; Tsubakihara Y; Akizawa T
    Int Heart J; 2012; 53(4):238-43. PubMed ID: 22878802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a More Permeable Dialysis Membrane on ESA Resistance in Hemodialysis Patients--A Pilot Investigation.
    Teatini U; Liebchen A; Nilsson LG; Beck W; Longhena GR
    Blood Purif; 2016; 41(1-3):80-6. PubMed ID: 26536083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.